Do analysts rate EVGN or CARM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SCPS or CARM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scopus BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, SCPS or CARM?

Scopus BioPharma has higher earnings, but lower revenue than Carisma Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Carisma Therapeutics $10.77M 0.00 -$60.48M $0.73 0.00

Is SCPS or CARM more profitable?

Scopus BioPharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Carisma Therapeutics -254.28% N/A -192.17%

Do analysts prefer CARM or SYRS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer CARM or NAVB?

Given Navidea Biopharmaceuticals' higher probable upside, analysts clearly believe Navidea Biopharmaceuticals is more favorable than Carisma Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CARM or NAVB more profitable?

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Navidea Biopharmaceuticals N/A N/A N/A

Do analysts rate ADTX or CARM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ADTX or CARM?

Aditxt has higher earnings, but lower revenue than Carisma Therapeutics. Aditxt is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.27 -$41.71M -$100.79 thousand N/A Carisma Therapeutics $10.77M 0.00 -$60.48M $0.73 0.00

Is ADTX or CARM more profitable?

Carisma Therapeutics has a net margin of -254.28% compared to Aditxt's net margin of -360,152.50%. Carisma Therapeutics' return on equity of 0.00% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Carisma Therapeutics -254.28% N/A -192.17%

Carisma Therapeutics (CARM) Competitors

$0.0008 0.00 (0.00%)

As of 09/15/2026

Compare

CARM vs. EVGN, SCPS, SYRS, NAVB, and ADTX

Should you buy Carisma Therapeutics stock or one of its competitors? Carisma Therapeutics's main competitors and comparable companies include Evogene (EVGN), Scopus BioPharma (SCPS), Syros Pharmaceuticals (SYRS), Navidea Biopharmaceuticals (NAVB), and Aditxt (ADTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Carisma Therapeutics compare to Evogene?

Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.12	-$8.48M	-$0.91	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

In the previous week, Evogene had 4 more articles in the media than Carisma Therapeutics. MarketBeat recorded 4 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.89 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media.

Company	Overall Sentiment
Evogene	Positive
Carisma Therapeutics	Neutral

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -694.18%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Evogene has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.02, suggesting that its stock price is 1,002% less volatile than the broader market.

10.4% of Evogene shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Evogene beats Carisma Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Carisma Therapeutics compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

44.3% of Carisma Therapeutics shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scopus BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scopus BioPharma has higher earnings, but lower revenue than Carisma Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Carisma Therapeutics	Neutral

Scopus BioPharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Carisma Therapeutics	-254.28%	N/A	-192.17%

Scopus BioPharma has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.02, meaning that its stock price is 1,002% less volatile than the broader market.

Summary

Scopus BioPharma and Carisma Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Carisma Therapeutics compare to Syros Pharmaceuticals?

Carisma Therapeutics (NASDAQ:CARM) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Syros Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Carisma Therapeutics has a beta of -9.02, suggesting that its share price is 1,002% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Carisma Therapeutics has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

Syros Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Summary

Carisma Therapeutics and Syros Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Carisma Therapeutics compare to Navidea Biopharmaceuticals?

Carisma Therapeutics (NASDAQ:CARM) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Navidea Biopharmaceuticals	Neutral

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Navidea Biopharmaceuticals	N/A	N/A	N/A

Given Navidea Biopharmaceuticals' higher probable upside, analysts clearly believe Navidea Biopharmaceuticals is more favorable than Carisma Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Navidea Biopharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Carisma Therapeutics. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Carisma Therapeutics has a beta of -9.02, meaning that its stock price is 1,002% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Carisma Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Carisma Therapeutics compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Aditxt has higher earnings, but lower revenue than Carisma Therapeutics. Aditxt is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.27	-$41.71M	-$100.79 thousand	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Carisma Therapeutics has a net margin of -254.28% compared to Aditxt's net margin of -360,152.50%. Carisma Therapeutics' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aditxt has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.02, indicating that its share price is 1,002% less volatile than the broader market.

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Carisma Therapeutics	Neutral

Summary

Carisma Therapeutics beats Aditxt on 7 of the 11 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARM vs. The Competition

Export

Metric	Carisma Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$33K	$12.54B	$7.22B	$14.93B
Dividend Yield	N/A	2.64%	2.57%	12.31%
P/E Ratio	0.00	794.70	273.81	25.33
Price / Sales	0.00	758.12	647.05	87.33
Price / Cash	N/A	85.42	76.40	50.90
Price / Book	0.00	10.47	10.35	6.24
Net Income	-$60.48M	$2.84B	$3.49B	$358.55M
7 Day Performance	N/A	-0.87%	-0.76%	-1.17%
1 Month Performance	N/A	1.00%	-1.32%	-4.26%
1 Year Performance	N/A	4.15%	21.16%	5.47%

Carisma Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARM Carisma Therapeutics	0.253 of 5 stars	$0.00 flat	N/A	-99.8%	$33K	$10.77M	0.00	20	Gap Down
EVGN Evogene	1.798 of 5 stars	$0.51 -5.6%	N/A	-58.7%	$4.69M	$3.85M	N/A	140	Gap Down
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	N/A	$17K	N/A	N/A	9
SYRS Syros Pharmaceuticals	N/A	$0.00 flat	N/A	-33.3%	$11K	$386K	N/A	120
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, SCPS, SYRS, NAVB, and ADTX

How does Carisma Therapeutics compare to Evogene?

Summary

How does Carisma Therapeutics compare to Scopus BioPharma?

Summary

How does Carisma Therapeutics compare to Syros Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Navidea Biopharmaceuticals?

Summary

How does Carisma Therapeutics compare to Aditxt?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, SCPS, SYRS, NAVB, and ADTX

How does Carisma Therapeutics compare to Evogene?

Do analysts rate EVGN or CARM?

Which has better earnings & valuation, EVGN or CARM?

Does the media prefer EVGN or CARM?

Is EVGN or CARM more profitable?

Which has more volatility & risk, EVGN or CARM?

Do institutionals & insiders hold more shares of EVGN or CARM?

Summary

How does Carisma Therapeutics compare to Scopus BioPharma?

Do insiders & institutionals believe in SCPS or CARM?

Do analysts prefer SCPS or CARM?

Which has higher earnings and valuation, SCPS or CARM?

Does the media prefer SCPS or CARM?

Is SCPS or CARM more profitable?

Which has more volatility and risk, SCPS or CARM?

Summary

How does Carisma Therapeutics compare to Syros Pharmaceuticals?

Does the media favor CARM or SYRS?

Do analysts prefer CARM or SYRS?

Which has more risk & volatility, CARM or SYRS?

Do institutionals and insiders have more ownership in CARM or SYRS?

Which has stronger earnings & valuation, CARM or SYRS?

Is CARM or SYRS more profitable?

Summary

How does Carisma Therapeutics compare to Navidea Biopharmaceuticals?

Does the media favor CARM or NAVB?

Is CARM or NAVB more profitable?

Do analysts prefer CARM or NAVB?

Do insiders & institutionals hold more shares of CARM or NAVB?

Which has stronger earnings and valuation, CARM or NAVB?

Which has more risk & volatility, CARM or NAVB?

Summary

How does Carisma Therapeutics compare to Aditxt?

Which has higher valuation and earnings, ADTX or CARM?

Is ADTX or CARM more profitable?

Do analysts rate ADTX or CARM?

Do insiders and institutionals have more ownership in ADTX or CARM?

Which has more risk & volatility, ADTX or CARM?

Does the media favor ADTX or CARM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools